Kersten Reider
Primary Care · Mount Penn, PANPI 1164033916
Payments from drug & device makers
Across 404 payments — averaging $298.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- KCI USA, Inc.$75K
- Solventum Corporation$42K
- Novo Nordisk$849
- AbbVie$550
- AstraZeneca$547
- Lilly USA, LLC$255
- plus $2K from 32 others
What the payments were for
- Consulting fees$2,8752%
- Speaking & faculty fees$80,41467%
- Travel & lodging$29,14224%
- Food & beverage$8,1057%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| KCI USA, Inc. | 123 | $74,729 |
| Solventum Corporation | 49 | $41,706 |
| Novo Nordisk | 44 | $849 |
| AbbVie | 35 | $550 |
| AstraZeneca(2 entities) | 33 | $547 |
| Lilly USA, LLC | 16 | $255 |
| Boehringer Ingelheim | 14 | $230 |
| Pfizer | 9 | $137 |
| Amgen | 8 | $130 |
| Astellas Pharma US Inc | 6 | $129 |
| Novartis | 6 | $120 |
| GSK | 5 | $100 |
| Dexcom, Inc. | 4 | $88 |
| Actelion Pharmaceuticals US, Inc. | 4 | $81 |
| Lundbeck LLC | 4 | $78 |
| Bayer | 4 | $73 |
| Otsuka America Pharmaceutical, Inc. | 3 | $67 |
| Boston Scientific | 2 | $61 |
| Phathom Pharmaceuticals, Inc. | 2 | $54 |
| Kowa Pharmaceuticals America, Inc. | 3 | $50 |
| Biogen | 3 | $45 |
| Sanofi Pasteur Inc. | 2 | $44 |
| Amarin Pharma, Inc. | 3 | $41 |
| Mannkind Corporation | 3 | $38 |
| Merck | 3 | $38 |
| Avanir Pharmaceuticals, Inc. | 2 | $37 |
| Viatris Specialty LLC | 2 | $36 |
| Molnlycke Health Care US, LLC | 1 | $28 |
| Sunovion Pharmaceuticals Inc. | 2 | $25 |
| Exact Sciences | 1 | $25 |
| Alnylam Pharmaceuticals Inc. | 1 | $23 |
| Si-bone, Inc. | 1 | $22 |
| Medtronic | 1 | $21 |
| Seqirus USA Inc | 1 | $20 |
| Shield Therapeutics Inc | 1 | $15 |
| Biodelivery Sciences International, Inc. | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Johnson & Johnson | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- V.A.C. VERAFLO$72,557
- V.A.C. VERAFLO CLEANSE CHOICE$48,409
- V.A.C. DERMATAC$44,643
- PREVENA$41,069
- ACTIV.A.C.$36,942
- 3M Cavilon$33,180
- PROMOGRAN PRISMA$17,981
- Bair Hugger$12,882
- DERMATAC$11,781
- Tegaderm$10,363
- ABTHERA$7,671
- SpotOn$6,822
- KERRAMAX CARE$6,799
- ABTHERA ADVANCE$6,622
- V.A.C. ULTA$6,161
- 3M Coban$5,766
- PREVENA RESTOR ARTHROFORM$5,553
- KERRACEL AG$5,250
- FISTULA SOLUTION$5,091
- V.A.C. INSTILL$4,746
How this compares
$120,535 in reported general payments places this provider in the 95th percentile of 300 primary care providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 57 | $50,199 |
| JardianceEmpagliflozin | 32 | $41,903 |
| TrulicityDulaglutide | 27 | $27,864 |
| JanuviaSitagliptin Phosphate | 20 | $16,440 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $13,048 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 16 | $10,198 |
| Levothyroxine Sodium | 135 | $3,002 |
| SteglatroErtugliflozin Pidolate | 19 | $2,496 |
| Oxycodone Hcl | 87 | $2,134 |
| Duloxetine Hcl | 53 | $1,815 |
| Gabapentin | 108 | $1,735 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 48 | $1,690 |
| Novolog FlexpenInsulin Aspart | 11 | $1,682 |
| Tamsulosin Hcl | 49 | $1,405 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 47 | $1,310 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Combivent Respimat | $230 | $52,10148 claims |
| PfizerEliquis | $137 | $50,19957 claims |
| Lilly USA, LLCTrulicity | $255 | $27,86427 claims |
| MerckJanuvia, Steglatro | $38 | $18,93639 claims |
| GSKTrelegy Ellipta | $100 | $13,04811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 300 primary care providers in Pennsylvania.
Other primary care in Mount Penn
- Teresa GiamboyPhiladelphia$21K
- Nicole IlgenfritzBethel Park$18K
- Galyna VorokhibPhiladelphia$12K
- Melissa BeansWarrington$12K
- Mollie McGuireJohnstown$11K
- Andrea MauriceNew Cumberland$11K
- Kendell SoglieroSmithfield$9K
- Minjung RegerDoylestown$9K
- Mackenzie HouserMedia$7K
- Kaylee BakerPhiladelphia$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.